A remarkable clinical response in advanced gastric cancer treated with trastuzumab plus capecitabine combination chemotherapy: A report of two cases.
capecitabine
gastric cancer
trastuzumab
Journal
Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
18
10
2018
accepted:
26
01
2019
entrez:
19
4
2019
pubmed:
19
4
2019
medline:
19
4
2019
Statut:
epublish
Résumé
When trastuzumab + capecitabine and cisplatin chemotherapy could not be conducted continuously because of severe adverse reactions to cisplatin, trastuzumab + capecitabine could be an alternative systemic chemotherapy options for metastatic or recurrent gastric cancer patients.
Identifiants
pubmed: 30997070
doi: 10.1002/ccr3.2056
pii: CCR32056
pmc: PMC6452495
doi:
Types de publication
Case Reports
Langues
eng
Pagination
714-718Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Surg Today. 2010 Apr;40(4):295-300
pubmed: 20339982
Gastric Cancer. 2017 Jan;20(1):1-19
pubmed: 27342689
Gastrointest Cancer Res. 2009 Nov;3(6):239-44
pubmed: 21151427
Clin Case Rep. 2019 Feb 26;7(4):714-718
pubmed: 30997070
Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907
pubmed: 20647400
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Gan To Kagaku Ryoho. 2016 Nov;43(12):2202-2204
pubmed: 28133269
Ann Oncol. 2008 Sep;19(9):1523-9
pubmed: 18441328
Gastric Cancer. 1998 Dec;1(1):10-24
pubmed: 11957040
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Jpn J Clin Oncol. 2011 Mar;41(3):307-13
pubmed: 21242182